Use of mHealth Application and Education to Increase Appropriateness of Thromboprophylaxis in Patients With Cancer
mHealth-supported Education Improves Thromboprophylaxis Appropriateness in Solid Tumors
Doctors will use a mHealth application to evaluate the risk of thrombosis and bleeding in patients with cancer.
調査の概要
状態
詳細な説明
This information will be shared with the patients to make an informed decision of using low molecular weight prophylaxis with heparin in case of high risk thrombosis a low-moderate risk of bleeding
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Alicante
-
Villajoyosa、Alicante、スペイン、03570
- Hospital Marina Baixa
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 years or older, and
- Recent diagnosis of a solid tumor or disease progression after partial or complete remission, and.
- Starting a new course of systemic anticancer therapy (chemotherapy, targeted therapy, hormone therapy, or immunotherapy) planned for at least 3 months
Exclusion Criteria:
- High risk of bleeding (e.g., advanced liver disease with coagulopathy), or
- Life expectancy under 3 months, or
- Hematologic malignancies, or
- Estimated glomerular filtration rate below 30 mL/min/1.73 m², or
- Platelet count below 50,000/mm³, or
- Body weight below 40 kg, or
- Current anticoagulant use.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Control group (preintervention)
Inclusion criteria:
Exclusion criteria:
In the preintervention period, we reviewed the electronic medical records of patients with a recent cancer diagnosis who were seen between January and June 2024. |
|
|
アクティブコンパレータ:postintervention
After using the mHealth application, the treating physician made the final decision regarding use of thromboprophylaxis after considering risk of thromboembolic disease, bleeding risk, renal function, drug interactions, and patient preferences. Postintervention period. For patients with cancer seen between January and June 2025, we collected the same variables from the electronic medical records as in the preintervention period. We selected the same calendar months to control for seasonality and enhance comparability between periods |
Physicians from the Internal Medicine and Oncology divisions attended a 2-hour session reviewing current guidelines for thromboprophylaxis in patients with cancer, followed by training on the mHealth TEVAPP application. TEVAPP is a web-based calculator of venous thromboembolism (VTE) risk scores for patients with cancer, developed by the Spanish Society of Medical Oncology (SEOM) (Spain; https://tevapp.es/; accessed December 15, 2024). The application was used to support clinical decision-making by integrating available clinical, laboratory, and treatment information at the initial visit before the initiation of a new systemic regimen. TEVAPP is a web-based calculator of VTE risk scores for patients with cancer, developed by SEOM (Spain; https://tevapp.es/; accessed December 15, 2024). It was used to support clinical decisions by integrating available clinical, laboratory, and treatment information at the initial visit before a new systemic regimen |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proprtion of patients with appropriate thromboprophylaxis use
時間枠:From first visit to oncology clinic up to three month of follow up
|
The primary outcome was the proportion of patients with appropriate prescription of thromboprophylaxis from the first medical oncology visit in the pre- and postintervention periods. The appropriateness of thromboprophylaxis was determined according to clinical practice guideline recommendations. Thromboprophylaxis was considered appropriate when weight-adjusted enoxaparin was prescribed for patients at intermediate or high thrombotic risk (6-month VTE probability >8%) and low bleeding risk, in the absence of other contraindications. Low bleeding risk was defined as an IMPROVE score <7 for patients hospitalized within the previous 30 days, or a Hokusai score <3 for nonhospitalized patients. In the version of TEVAPP used, the latter corresponded to fewer than 60% of bleeding risk factors. Withholding thromboprophylaxis was considered appropriate for patients at low thrombotic risk or with contraindications to anticoagulation. |
From first visit to oncology clinic up to three month of follow up
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of venous thromboembolic disease
時間枠:From first visit the the Oncology Clinic up to three months of follow-up
|
We compared the incidence of VTE disease in the pre- and postintervention periods. VTE is suspected based on clinical symptoms and signs and confirmed with objective testing. The diagnostic approach includes assessment of pretest clinical probability, selective D-dimer testing, and imaging. Suspected DVT: Clinical probability is estimated using the 2-level Wells score. Patients with a likely score (≥2 points) should undergo proximal leg-vein compression ultrasonography, preferably with Doppler assessment; D-dimer may be used selectively when ultrasound is negative or clinical probability is low. Suspected PE: Clinical probability is estimated using a validated score such as the Wells score. Definitive diagnosis is usually made with computed tomography pulmonary angiography (CTPA); a ventilation-pe |
From first visit the the Oncology Clinic up to three months of follow-up
|
|
Incidence of bleeding
時間枠:From first visit the the Oncology Clinic up to three months of follow-up
|
We compared the bleeding events in the pre- and postintervention periods classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical site or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome), or bleeding associated with a hemoglobin decrease of ≥2 g/dL or transfusion of ≥2 units of whole blood or packed red blood cells. Clinically relevant non-major bleeding was defined as overt bleeding not meeting major bleeding criteria but requiring hospitalization, medical or surgical intervention, or interruption or modification of anticoagulant therapy |
From first visit the the Oncology Clinic up to three months of follow-up
|
|
Incidence of death
時間枠:From first visit the the Oncology Clinic up to three months of follow-up
|
We compared all-cause mortality in the pre- and postintervention periods. All-cause mortality was defined as death from any cause occurring during the study follow-up period. |
From first visit the the Oncology Clinic up to three months of follow-up
|
協力者と研究者
捜査官
- 主任研究者:Javier Ena, MD、Hospital Marina Baixa
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Univeridad Miguel Hernandez
- UGP-24-212 (その他の助成金/資金番号:Fundación Eugenio Rodriguez Pascual)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Upon reasonable request with patient de-identification
IPD 共有時間枠
October 2026, to October 2027
IPD 共有アクセス基準
Javier Ena, MD. Personal computer
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。